Moderna shares soar over 16% over coronavirus vaccine trial result

US drugmaker Moderna's shares soared by more than 16 per cent after the company said its potential vaccine to prevent Covid-19 produced a "robust" immune response in all 45 patients in its early stage human trial, CNBC reported.

All the 45 patients in the trial produced neutralising antibodies which are believed to be important for building immunity and provided more promising data that the vaccine may give some protection against the coronavirus, according to the findings published in the New England Journal of Medicine.

After two vaccinations, the vaccine elicited a "robust" immune response in all participants in all dose cohorts, Moderna